Newsquawk Logo

Regeneron Pharmaceuticals Inc. (REGN) Q1 2026 (USD): EPS 9.47 (exp. 8.80), Revenue 3.61bln (exp. 3.47bln)

Regeneron Pharmaceuticals' Q1 2026 earnings report reveals a notable earnings per share (EPS) of $9.47, outperforming expectations of $8.80, and revenue of $3.61 billion, surpassing the forecast of $3.47 billion.

Newsquawk StaffPublished On the live feed at — 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Blackstone (BX) announces strategic focus for its private credit fund, targeting market leaders in verticals less susceptible to AI-related disruption

Shenzhen, China has eased purchase restrictions relating to house prices. Measures effective from April 30th.

Regeneron Pharmaceuticals Inc. (REGN) Q1 2026 (USD): EPS 9.47 (exp. 8.80), Revenue 3.61bln (exp. 3.47bln)

Entergy (ETR) Q1 2026 (USD): EPS 0.86 (exp. 0.84), Revenue -- (exp. 2.89bln); sees FY Outlook Adj. EPS 4.25-4.45 (exp. 4.39)

Iran is expected to submit a revised peace proposal soon, CNN reports citing sources

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.

Sales Breakdown (USD)

  • Dupizent 4.9bln, +33%
Context

The strong performance is largely driven by a 33% increase in sales of Dupizent, indicating robust demand and potential for future growth, which may positively influence sentiment toward biotech stocks and attract investor interest in the sector.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.